

Clive Holmes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/12193193/clive-holmes-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

81
papers

20,975
citations

41
h-index

91
g-index

91
ext. papers

25,386
ext. citations

13.7
avg, IF

6.16
L-index

#	Paper	IF	Citations
81	New insights into the genetic etiology of Alzheimer's disease and related dementias.. <i>Nature Genetics</i> , 2022 ,	36.3	27
80	Inflammation in dementia with Lewy bodies.. <i>Neurobiology of Disease</i> , 2022 , 105698	7.5	2
79	Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer's Disease: A Review.. <i>Frontiers in Human Neuroscience</i> , 2022 , 16, 866434	3.3	1
78	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021 , 12, 3417	17.4	23
77	The Locus Coeruleus in Aging and Alzheimer's Disease: A Postmortem and Brain Imaging Review. <i>Journal of Alzheimers Disease</i> , 2021 , 83, 5-22	4.3	10
76	The Role of Adaptive and Innate Immunity in Alzheimer's Disease 2021 , 213-232		
75	Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. <i>Translational Psychiatry</i> , 2020 , 10, 267	8.6	9
74	Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer's disease: an observational clinical study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 1219-1226	5.5	6
73	Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. <i>Translational Psychiatry</i> , 2019 , 9, 154	8.6	31
72	Persistent neuropathological effects 14 years following amyloid- β immunization in Alzheimer's disease. <i>Brain</i> , 2019 , 142, 2113-2126	11.2	74
71	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease. <i>PLoS ONE</i> , 2019 , 14, e0218111	3.7	12
70	Microglial motility in Alzheimer's disease and after A β 2 immunotherapy: a human post-mortem study. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 174	7.3	18
69	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019 , 51, 414-430	36.3	917
68	Downregulated apoptosis and autophagy after anti-A β immunotherapy in Alzheimer's disease. <i>Brain Pathology</i> , 2018 , 28, 603-610	6	12
67	Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 62, 244.e1-244.e8	5.6	25
66	Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?. <i>Autoimmunity Reviews</i> , 2018 , 17, 919-925	13.6	21
65	Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 88	7.3	32

64	Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnesic Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2018 , 75, 1114-1123	17.2	50
63	Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2017 , 31, 147-168	4.6	108
62	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017 , 49, 1373-1384	36.3	508
61	Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 1205-1216	3.9	32
60	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. <i>Health Technology Assessment</i> , 2017 , 21, 1-192	4.4	19
59	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016 , 46, 235.e1-9	5.6	33
58	Shared genetic contribution to Ischaemic Stroke and Alzheimer's Disease. <i>Annals of Neurology</i> , 2016 , 79, 739-747	9.4	42
57	Targeting innate immunity for neurodegenerative disorders of the central nervous system. <i>Journal of Neurochemistry</i> , 2016 , 138, 653-93	6	87
56	Effect of amyloid- β immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3 β <i>Neuropathology and Applied Neurobiology</i> , 2015 , 41, 445-57	5.2	17
55	Neuroinflammation in Alzheimer's disease. <i>Lancet Neurology</i> , 2015 , 14, 388-405	24.1	2760
54	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology</i> , 2015 , 14, 1171-81	24.1	101
53	Common polygenic variation enhances risk prediction for Alzheimer's disease. <i>Brain</i> , 2015 , 138, 3673-84	11.2	227
52	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimers and Dementia</i> , 2015 , 11, 658-71	1.2	146
51	Effect of active A β immunotherapy on neurons in human Alzheimer's disease. <i>Journal of Pathology</i> , 2015 , 235, 721-30	9.4	28
50	Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. <i>Neurology</i> , 2015 , 84, 2161-8	6.5	147
49	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. <i>Nature</i> , 2014 , 505, 550-554	50.4	345
48	A β immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. <i>Acta Neuropathologica</i> , 2014 , 128, 777-89	14.3	32
47	Microglial priming in neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2014 , 10, 217-24	15	664

46	Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. <i>PLoS ONE</i> , 2014 , 9, e94661	3.7	90
45	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013 , 45, 1452-8	36.3	2714
44	Inflammatory components in human Alzheimer's disease and after active amyloid- β immunization. <i>Brain</i> , 2013 , 136, 2677-96	11.2	165
43	Male sex hormones and systemic inflammation in Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , 2013 , 27, 153-6	2.5	38
42	Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2013 , 202, 121-8	5.4	34
41	Drug repositioning for Alzheimer's disease. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 833-46	64.1	191
40	Systemic and central immunity in Alzheimer's disease: therapeutic implications. <i>CNS Neuroscience and Therapeutics</i> , 2012 , 18, 64-76	6.8	25
39	Donepezil and memantine for moderate-to-severe Alzheimer's disease. <i>New England Journal of Medicine</i> , 2012 , 366, 893-903	59.2	483
38	The role of variation at <i>APP</i> , <i>PSEN1</i> , <i>PSEN2</i> , and <i>MAPT</i> in late onset Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2012 , 28, 377-87	4.3	47
37	Systemic inflammation and Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2011 , 39, 898-901	5.1	51
36	Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2011 , 378, 403-11	4.0	348
35	A multi-center study of ACE and the risk of late-onset Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2011 , 24, 587-97	4.3	29
34	Impact of 123I-FP-CIT (DaTSCAN) SPECT on the diagnosis and management of patients with dementia with Lewy bodies: a retrospective study. <i>Nuclear Medicine Communications</i> , 2011 , 32, 298-302	1.6	11
33	Common variants at <i>ABCA7</i> , <i>MS4A6A/MS4A4E</i> , <i>EPHA1</i> , <i>CD33</i> and <i>CD2AP</i> are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011 , 43, 429-35	36.3	1421
32	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2011 , 156B, 764-71	3.5	15
31	Determining the minimum clinically important differences for outcomes in the DOMINO trial. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 812-7	3.9	96
30	Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. <i>PLoS ONE</i> , 2010 , 5, e13950	3.7	276
29	Concordant association of insulin degrading enzyme gene (<i>IDE</i>) variants with <i>IDE</i> mRNA, A β , and Alzheimer's disease. <i>PLoS ONE</i> , 2010 , 5, e8764	3.7	40

28	Microglia in neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2010 , 6, 193-201	15	1119
27	Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. <i>Alzheimer's Research and Therapy</i> , 2010 , 2, 1	9	142
26	Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2010 , 120, 13-20	14.3	67
25	Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. <i>Acta Neuropathologica</i> , 2010 , 120, 369-84	14.3	105
24	DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. <i>Trials</i> , 2009 , 10, 57	2.8	36
23	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009 , 41, 1088-93	36.3	2018
22	Role of infection in the pathogenesis of Alzheimer's disease: implications for treatment. <i>CNS Drugs</i> , 2009 , 23, 993-1002	6.7	52
21	Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. <i>Lancet, The</i> , 2008 , 372, 216-23	40	1140
20	Systemic infections and inflammation affect chronic neurodegeneration. <i>Nature Reviews Immunology</i> , 2007 , 7, 161-7	36.5	747
19	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. <i>Lancet Neurology, The</i> , 2007 , 6, 305-13	24.1	488
18	Imaging in dementia with Lewy bodies: a review. <i>Nuclear Medicine Communications</i> , 2007 , 28, 511-9	1.6	26
17	Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. <i>Nuclear Medicine Communications</i> , 2007 , 28, 451-6	1.6	27
16	Abeta species removal after abeta42 immunization. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006 , 65, 1040-8	3.1	218
15	The Molecular Pathology of Severe Dementia 2006 , 33-40		
14	Association between dementia and infectious disease: evidence from a case-control study. <i>Alzheimer Disease and Associated Disorders</i> , 2005 , 19, 91-4	2.5	132
13	Reply to Bpecificity of mechanisms for plaque removal after Aβ immunotherapy for Alzheimer disease. <i>Nature Medicine</i> , 2004 , 10, 118-119	50.5	11
12	Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. <i>Age and Ageing</i> , 2003 , 32, 200-4	3	59
11	Depression in Alzheimer's disease: the effect of serotonin receptor gene variation. <i>American Journal of Medical Genetics Part A</i> , 2003 , 119B, 40-3		43

10	Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. <i>Nature Medicine</i> , 2003 , 9, 448-52	50.5	1259
9	The clinical phenotype of familial and sporadic late onset Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002 , 17, 146-9	3.9	10
8	Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. <i>Nature Genetics</i> , 1999 , 21, 71-2	36.3	236
7	Clinical involvement in anti-dementia drug trials—why bother?. <i>International Journal of Geriatric Psychiatry</i> , 1999 , 14, 258-260	3.9	2
6	Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. <i>British Journal of Psychiatry</i> , 1999 , 174, 45-50	5.4	267
5	Previous psychiatric history as a risk factor for late-life dementia: a population-based case-control study. <i>Age and Ageing</i> , 1998 , 27, 181-8	3	38
4	The Camberwell Dementia Case Register. <i>International Journal of Geriatric Psychiatry</i> , 1996 , 11, 369-375	3.9	20
3	Dementia known to mental health services: First findings of a case register for a defined elderly population. <i>International Journal of Geriatric Psychiatry</i> , 1995 , 10, 875-881	3.9	7
2	New insights on the genetic etiology of Alzheimer's and related dementia		25
1	Gene-Based Analysis in HRC Imputed Genome Wide Association Data Identifies Three Novel Genes For Alzheimer's Disease		1